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Abstract
Background: Many studies have reported an increased risk of developing a second primary malignancy (SPM) of
the breast in women treated for thyroid cancer. In this study, we investigated several potential risk factors for this
association. The aim of this retrospective cohort study was to identify a subgroup of women surgically treated for
papillary thyroid cancer that may benefit from more careful breast cancer screening.
Methods: A total of 101 women surgically treated for papillary thyroid cancer from 1996 to 2009 with subsequent
follow-up were interviewed by phone regarding personal risk factors and lifestyle habits. Only 75 questionnaires
could be evaluated due to a 25.7% rate of patients not retrieved or refusing the interview. Data analysis was
performed using a multivariate logistic model.
Results: The standardised incidence ratio (SIR) for breast cancer was 3.58 (95% IC 1.14 - 8.37). Our data suggest a
protective effect of multiparity on the development of a SPM of the breast (O.R. 0.15; 95% IC 0.25 - 0.86).
Significant associations were not found with other known risk factors including Body Mass Index (BMI), age at first
tumour, concurrent metabolic diseases, smoking, physical activity and familiarity.
Conclusions: This study confirms that a higher incidence of SPM of the breast is observed in women treated for
papillary thyroid cancer. Additionally, this risk is increased by nulliparity, thus a strict breast screening program for
nulliparous women treated for thyroid cancer may be advisable.
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Background
Papillary thyroid cancer is the most commonly observed
endocrine neoplasm. Its overall age standardised rate in
Italy is 9.1 cases/100.000 persons/year, even if its incidence
is higher in women (14.3). The mortality rate is much
lower, accounting 0.4 death/100.000 [1]. Because thyroid
cancer survivors may live for several decades following
diagnosis, they may develop a second primary malignancy
(SPM). In a meta-analysis conducted by Subramanian
et al., 1409 publications were reviewed, and they found
that breast carcinoma is the most frequent SPM in women
treated for thyroid carcinoma [2]. Several large studies
analysed the incidence of SPM of the breast using cancer
registries [3-5], but these studies did not focus on possible
risk co-factors, such as the lifestyle or family and past
medical history of the women. The present study exam-
ined common risk factors for breast carcinoma in a cohort
of women surgically treated for papillary thyroid carci-
noma. Based on these factors, our goal was to identify a
subgroup of women with an increased risk of developing a
S P Mo ft h eb r e a s tt h a tm a yb e n e f i tf r o mm o r ec a r e f u l
mammary screening.
Methods
Women with a histological diagnosis of papillary thyroid
cancer and available follow-up data were selected from a
database of patients surgically treated from 1996 to 2009
for thyroid disease at one of the Departments of Surgery
of Policlinico Umberto I in Rome. A total of 101 women
with papillary thyroid cancer were present in the
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cohort study. A questionnaire was designed to guide a
phone interview to investigate patients’ personal risk fac-
tors and lifestyle habits (additional file 1). All patients
were called and interviewed by the same individual. Each
interview lasted approximately ten minutes. In total,
75 interviews were conducted. Of the selected 101
women, 26 of these patients (25.7%) were unavailable for
interviews (2 did not survive, 22 could not be reached via
phone and 2 refused the interview).
Data analysis was performed using univariate and mul-
tivariate logistic models. In addition, the ratio between
expected and observed incidence of breast cancer during
the follow-up period was calculated (SIR: standardised
incidence ratio = expected/observed). Confidence inter-
vals were calculated from a poissonian distribution for
standardised rates, according to [6].
Results
Of the 75 patients who answered the questionnaire, the
mean age at the diagnosis of papillary cancer was 57.35 ±
12.75 years, with a mean follow-up period at the moment
of the interview of 74.52 ± 12.75 months (6.21 ± 1.06
years). In the follow up period after the diagnosis of papil-
lary thyroid cancer, 7 SPMs of the breast were observed.
All these 7 patients had been already operated at the
moment of the interview and their diagnosis of breast can-
cer had been histologically confirmed. The mean time
interval between the diagnosis of thyroid cancer and the
subsequent diagnosis of breast cancer was 5.80 ± 3.24
years. Two cases of detected breast cancer occurred within
2 years from the papillary carcinoma diagnosis and they
were not considered in the SIR calculation. According to
many other similar studies[3,4], these cases were consid-
ered to occur concurrently to thyroid cancer.
For SIR calculation we considered an expected inci-
dence of 300 new cases/y/100000 women, (i.e., 0.225 new
cases/y/75 women). This incidence is based on Piscitelli
et al. [7], which was chosen because this study gave us a
good estimate of the incidence in an Italian population,
in the same time period as our study and for a population
similar in age. During the follow-up period, the expected
incidence was 1.40 cases (0.225*6.21); however, we actu-
ally observed 5 cancer cases, resulting in a calculated SIR
of 3.58 (95% IC 1.14 - 8.37). Univariate analysis indicated
a protective effect of multiparity on the onset of a breast
SPM (O.R. 0.15; 95% IC 0.25 - 0.86) (Table 1). Parity was
also an independent risk factor based on multivariate
analysis. Significant associations were not detected with
other known risk factors, such as BMI, age at first
tumour, concurrent metabolic diseases, smoking, physical
activity and family history (Table 1).
The characteristics of the study population are pro-
vided in Table 2.
Twenty-four patients (32%) did not follow a regular
breast screening program. Because we only conducted a
phone interview and not a clinical exam of the women,
the actual number of SPMs of the breast could have
been underestimated.




The incidence of thyroid cancer has almost doubled in
Italy between the periods 1991-1995 and 2001-2005. This
trend is almost exclusively due to an increase in papillary
thyroid cancer (PTC) [8]. The mortality rate for patients
diagnosed with thyroid cancer, however, has declined [9],
and the 15 year survival rate is approximately 80% [10].
Due to this prolonged survival time, development of a
SPM is becoming an actual possibility for thyroid cancer
survivors. For example, it is known that women treated
for thyroid cancer have an increased incidence of subse-
quent breast cancer compared to the general population
[11], and our research confirms this finding. We identi-
fied 7 patients with breast cancer among the 75 women
previously treated for papillary thyroid cancer. Five of the
cases were documented more than two years from the
initial diagnosis of PTC. The mean follow-up period was
6.21 years, resulting in a SIR of 3.58 (95% IC 1.14-8.37).
In a meta-analysis conducted by Subramanian et al. [2],
a pooled SIR of 1.25 (95% CI 1.17-1.32) was calculated
for breast SPMs from a group of 83292 patients. This SIR
was lower than our calculated SIR. It is important to note
that the sample size used in our study was smaller and
our confidence interval was larger than those calculated
in the meta-analysis, but our study includes the SIR value
of the meta-analysis (i.e., 1.25). Furthermore, we found
that 24 of the 75 women (32%) questioned did not follow
a regular breast screening program; therefore, the num-
ber of breast SPMs detected could have been an underes-
timate. Additionally, Adjadj et al. [4] observed an
increased risk of breast cancer among thyroid cancer
patients and was unable to detect a significant correlation
with treatment (radiotherapy or radioactive iodine ther-
apy) of the initial cancer. Because the mammary gland
has the same sodium-iodine symport as the thyroid
gland, radioactive iodine could be implicated in breast
carcinogenesis. Additionally, radiotherapy treatment
could induce women of childbearing age to delay preg-
nancy, and parity is a known protective factor for breast
cancer, especially in younger women [12].
Although Canchola et al. [4] detected a higher inci-
dence only of in situ SPM breast cancer, we observed
an increased risk of invasive breast cancer. Chen et al.
(2001) [3] and Brown et al. (2008) [11] observed a
higher incidence of SPM of the breast in 25-49-year-old
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older women. Despite these results, we were unable to
detect a significant correlation between the incidence of
breast cancer and young age. It is important to note
that the mean age at first tumour diagnosis in our sam-
ple population was 57.35 ± 12.75 years. This mean age
was higher than that observed in the series from Chen
et al. and Brown et al., reflecting the general trend for
the mean age at tumour onset in Italian populations [9].
According to Rubino et al. and Sawka et al. [13,14],
thyroid cancer patients treated with radioactive iodine
have an increased risk of developing several SPMs,
including leukemia or bone cancer, but not breast can-
cer. Because 72 of the 75 patients (96%) were treated
with radioactive iodine, we were unable to assess the
correlation between breast SPM risk and radioactive
iodine treatment in our study.
Risk factors
Previously, the majority of studies on the incidence of
SPM following thyroid cancer were based on cancer
registries. Consequently, they could not take detailed per-
sonal data into account, and important information such
as life style and personal risk factors of patients were not
analysed. Using phone interviews, we investigated several
potential risk factors involved in the association between
thyroid and subsequent breast cancers. The aim of this
retrospective cohort study was to identify a subgroup of
women surgically treated for papillary thyroid cancer that
may necessitate a more careful mammary screening.
Based on our analysis, we observed a significant protec-
tive effect of multiparity for SPM of the breast. Obesity
has been associated with increased incidence of thyroid
cancer [15]. In our study, the majority of patients were
overweight with a mean BMI of 26.83 ± 4.74 Kg/m
2.W e
were unable to detect a significant association between
weight and risk using both univariate and multivariate
analyses. Despite the fact that women with a first-degree
relative suffering from breast cancer have a higher risk of
developing primary breast cancer [12], a significant asso-
ciation was not detected with family history.
Study limitations and perspectives for the future
This retrospective cohort study only included 101 patients,
thus a larger patient population is needed to confirm our
findings. Furthermore, we were unable to detect a signifi-
cant association between young age and SPM, but the
mean age for our sample population was higher than
those reported in other studies [3,4,10].
Age of the first live birth as well as the number of chil-
dren could be relevant information. Nevertheless, in this
study we tried to keep the interview as short and simple as
possible and to consider only dichotomous variables for
calculation. Starting now from the consideration that
childbearing is a risk factor, more addressed and large stu-
dies are needed to define in details extent and meaning of
this finding. An additional limitation to the study was the
loss of 25.7% of the initial 101 patients due to interview
unavailability. It is possible that our results may have been
different if the other 22 interviews had been collected,
even if there is not a reason to presume a specific direction
for this potential bias. In fact, personal characteristics of
this sub-group, as recorded in the database, were similar
to the rest of the sample.
The pathophysiologic relationship between thyroid and
breast cancer is not clearly understood. Potential hypoth-
eses for the link between these tissues include a genetic
predisposition, dysregulation of the immune system or a
hormonal cause. Additionally, the observed increased
incidence of breast SPM could be artificial because
w o m e np r e v i o u s l yt r e a t e df o rc a n c e rm a yb em o r ec a u -
tious with their health.
Hall et al. [16] demonstrated in vitro that thyroid hor-
mones (T3) may function to mimic or enhance the effect
of oestrogens on breast cancer cell proliferation. Based on
this information, it is clear that the effect of high l-
Table 1 Logistic regression analysis of measured factors
Variable Univariate analysis Multivariate analysis
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Age at first tumor 1.06 (0.98 - 1.14) 0.14 1.07 (0.97 - 1.18) 0.16
Weight 0.96 (0.89-1.04) 0.33 0.98* (0.90-1.07) 0.65*
Child 0.15 (0.03-0.86) 0.03 0.08 (0.01-0.94) 0.04
Smoke 5.33 (0.59-48.33) 0.72 4.79 (0.43-53.25) 0.20
Physical activity 0.32 (0.03-2.88) 0.31 0.17 (0.01-4.15) 0.28
Concurrent metabolic diseases 0.82 (0.15 - 4.40) 0.82 0.08 (0.00 - 1.56) 0.10
Family history of breast cancer 2.65 (0.49-14.41) 0.26 1.06* (0.10 - 0.88) 0.96*
The multivariate model considered as the most accurate includes as selected covariate only: age at first tumor, child, smoke, physical activity and concurrent
metabolic diseases, expressed as dichotomous variables (yes/no). Weight and family history were excluded due to high p-value i.e. p > 0.6.
Hosmer Lemeshow test for goodness of fit was not statistically significant (p = 0.07), indicating a good quality of the model itself.
* the odds ratios for weight and family history of breast cancer are from the “full” model which includes all the covariates in the table.
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monal therapy following thyroidectomy in thyroid cancer
patients should to be investigated. According to the
experimental hypothesis that high l-thyroxine doses could
enhance the risk of breast cancer, hormone replacement
therapy for postmenopausal women should also be investi-
gated as a possible risk factor. This information was too
detailed to be collected by a phone interview in this study,
because of the large number of commercially available
products.
Conclusions
This study confirms that there is an increased incidence of
breast SPM in women treated for papillary thyroid cancer.
With the exception of nulliparity, we were unable to detect
significant associations between the incidence of SPM and
several known risk factors. From a methodological per-
spective, the questionnaire design was appropriate. It
allowed for a detailed phone interview that only required
10 minutes of time from each patient. Based on our find-
ings, a strict breast screening program for nulliparous
women treated for thyroid cancer may be advisable.
Although we were able to detect a significant association,
larger studies are necessary to confirm our findings and
investigate other potential risk factors (e.g., suppressive
hormonal therapy).
Additional material
Additional file 1: the questionnaire for the interview. a 25 items
questionnaire to collect information about risk factors related to personal
habits and life-style. Tested for a phone interview of about 10 minutes.
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